Bladder cancer (BC) represents a significant global health challenge with notable incidence and mortality rates. Despite treatment advancements, its management remains complex, requiring a multidisciplinary approach. Imaging techniques play a pivotal role in diagnosis, staging, and treatment planning by aiding lesion localization, differentiation, and assessment of tumor extent. Primary modalities like computed tomography and MRI offer detailed anatomic insights. Imaging provides valuable insights into tumor biology, vascular patterns, and molecular profiles, enabling personalized medicine strategies to optimize therapeutic efficacy and minimize adverse effects, crucial for improving BC management and prognosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ucl.2024.07.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biparametric magnetic resonance imaging as a diagnostic tool for differentiating RCC and renal pseudotumor in CKD patients.
Urologia
January 2025
Department of Urology and Renal Transplantation, Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow, Lucknow, Uttar Pradesh, India.
Introduction: Pseudotumors are benign lesions which may mimic like a malignant tumor on conventional imaging. They are formed in kidneys which are scarred and deformed by chronic pyelonephritis, glomerulonephritis, trauma or infarction. There is a diagnostic dilemma in most of the cases as to differentiate RCC and pseudotumors.
View Article and Find Full Text PDFScreening and prognostic roles of renal volumetry and scintigraphy in the assessment of living kidney transplant donors, considering the early recovery of the residual renal function.
BMC Nephrol
January 2025
Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan.
Background: The existing criteria for living kidney donors (LKDs)in Japan are controversial. We evaluated the roles of computed tomography volumetry (CTV) and 99 m Tc-diethylenetriamine penta-acetic acid (DTPA) scintigraphy in assessing preoperative and postoperative renal function and predicting early recovery of residual renal function.
Methods: We retrospectively reviewed the medical charts of 175 consecutive LKDs who underwent donor nephrectomy (DN) at our institution between 2006 and 2022.
Biochemical failure-free survival of F-rhPSMA-7 and F-flotufolastat PET-guided salvage radiotherapy for patients with recurrent prostate cancer.
Sci Rep
January 2025
Department of Nuclear Medicine, TUM University Hospital rechts der Isar, TUM School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany.
Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) has improved localization of prostate cancer (PC) lesions in biochemical recurrence (BCR) for salvage radiotherapy (SRT). We conducted a retrospective review of patients undergoing F-rhPSMA-7 or F-flotufolastat (F-rhPSMA-7.3)-PET-guided SRT compared with conventional-SRT (C-SRT) without PET.
View Article and Find Full Text PDFPrognostic value of MR visibility/invisibility in men on Active Surveillance.
Prostate Cancer Prostatic Dis
January 2025
Division of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
Objective: We sought to determine, in a prospective long term cohort, the prognostic value of negative MR imaging with respect to upgrading and need for intervention in men on AS.
Method: A long term prospective single centre study of men on Active surveillance with MR imaging. Primary outcome was upgrading on biopsy and rate of intervention.
Low baseline IsoPSA Index is associated with a Prolonged Low Risk of Clinically Significant Prostate Cancer Diagnosis in Men with an Elevated PSA.
Urology
January 2025
Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.
Objective: To compare the rate of diagnosing clinically significant prostate cancer (csPCa) in men with elevated PSA stratified by baseline IsoPSA Index, thus assessing IsoPSA's intermediate-term predictive ability for csPCa.
Material And Methods: Single-center retrospective review of consecutive patients (n=1578) who underwent IsoPSA testing from November 2016-August 2022. Data dichotomized into patients with low(≤6) and high IsoPSA Indices (>6).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!